Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN) in a research note issued to investors on Thursday. The firm set a “sell” rating on the stock.

Oragenics Price Performance

NYSE OGEN opened at $0.26 on Thursday. The firm has a market capitalization of $3.18 million, a P/E ratio of -0.04 and a beta of 0.85. Oragenics has a 1-year low of $0.24 and a 1-year high of $3.43. The business’s 50-day simple moving average is $0.29 and its 200-day simple moving average is $0.35.

About Oragenics

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.